Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9-DUO Trial: Dual PCSK9 Inhibition in High Cardiovascular Risk
NCT07581808Phase 4Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of inclisiran, alirocumab in hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), sponsored by University Medical Centre Ljubljana. Started May 2026; status: recruiting.
02
Drugs
inclisiranalirocumab
03
Conditions
hypercholesterolemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07581808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581808.